64.75 0.00 (0.00%)
After hours: 7:03PM EDT
|Bid||63.50 x 800|
|Ask||64.75 x 29200|
|Day's Range||64.50 - 65.07|
|52 Week Range||48.88 - 65.90|
|PE Ratio (TTM)||124.04|
|Earnings Date||Oct 16, 2018 - Oct 22, 2018|
|Forward Dividend & Yield||1.12 (1.73%)|
|1y Target Est||71.06|
Biotech stocks have a reputation for risk. Many more established biotech stocks exist that have built drug pipelines and revenue streams. With these pipelines and revenue streams, analysts are able to predict potential profits for years to come.
As discussed, Amgen (AMGN) is focused on discovering, developing, and delivering innovative human therapeutics. On July 31, Amgen announced the breaking of ground at its new biomanufacturing plant at its West Greenwich, Rhode Island, campus. Overall, Amgen has invested over ~$1.5 billion in the Rhode Island campus, which has an area of over 500,000 square feet, including manufacturing, utility, laboratory, and administrative space.
Abbott’s four main operating segments—nutrition, medical devices, prescription drugs in emerging markets and medical diagnostics—are all expanding at faster rates than the typical large-cap stock. Adjusted earnings per share grew by 17% over that same period. Maintaining that pace over the long term will be a challenge, but Wall Street expects sales growth in the next several years will be almost as strong.
The fact of the matter is, however, for many investors the bulk of their total investing profits reaped for the long haul will come from dividends… even dividends that are reinvested in the companies paying them. With that as the backdrop, here’s a rundown of the market’s highest-quality dividend stocks … dividend payers that could be considered the aristocrats among the market’s income-oriented investments.
In 2012, Baxter International (BAX) adopted a $2 billion share buyback program. In November 2016 and February 2018, the company increased the program by $1.5 billion each.
Give Me Your Hand is a finely crafted story of obsession. Kit Owens and Diane Fleming are high school friends and rivals. Both are outsiders: hyper-intelligent and ambitious, each is determined to make ...
Bausch Health Companies’ (BHC) wholly-owned subsidiary Salix Pharmaceuticals reported revenue of $441 million in the second quarter compared to $387 million in the second quarter of 2017, which reflected ~14% YoY (year-over-year) growth.
During its Q2 2018 earnings release on July 25, Boston Scientific (BSX) updated its fiscal 2018 guidance. The company raised its fiscal 2018 sales guidance and maintained its adjusted EPS guidance at $1.37–$1.41, representing growth of 9%–12%.
Haemonetics (HAE) is a leading healthcare company in blood management solutions. Its devices portfolio includes surgical and diagnostic devices as well as blood and plasma center devices. The software portfolio includes blood center software, plasma center software, and hospital software.
In its fiscal third-quarter conference call, Hologic (HOLX) narrowed the projected range of its fiscal 2018 EPS from $2.22–$2.27 to $2.24–$2.26. Considering the midpoint of the updated EPS guidance range, the company expects YoY (year-over-year) EPS growth of ~10.8% for fiscal 2018.
During its fiscal third quarter conference call, Hologic (HOLX) raised its fiscal 2018 non-GAAP revenue guidance from $3.18 billion–$3.21 billion to ~$3.21 billion–$3.22 billion. So, its YoY (year-over-year) reported revenue growth rate for fiscal 2018 is expected to be 4.8%–5.3%, higher than the previously projected range of 4.0%–4.9%.
In the fiscal third quarter, Hologic reported non-GAAP EPS of ~$0.58, which was a YoY rise of 16.0%. Hologic surpassed its revenue and EPS guidance for the fiscal third quarter. Hologic’s Diagnostics business posted a recovery compared to the fiscal second quarter, and its Surgical business has posted gradual improvement since the fiscal first quarter.
In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35. Boston Scientific’s strong earnings growth in the quarter was due to its strong profit and loss metrics. The company is working on improving cost efficiencies through its end-to-end business by streamlining and automation initiatives, expanding global shared services, and leveraging global sourcing teams. Peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Thermo Fisher Scientific (TMO) reported adjusted EPS growth of 17.7%, 30.5%, and 19. ...
On July 25, Boston Scientific (BSX) released its Q2 2018 earnings results. It reported revenue of $2.49 billion, exceeding Wall Street’s estimate of ~$2.46 billion and coming in at the higher end of the company’s $2.45 billion–$2.5 billion guidance.
Boston Scientific (BSX) announced its Q2 2018 results on July 25, exceeding analysts’ estimates. That day, BSX stock rose ~2.2%, while the iShares US Medical Devices ETF (IHI) rose ~1.4%. BSX comprises ~4.7% of IHI.
- FDA approval of new software upgrade for Abbott's deep brain stimulation therapy enables advanced, patient-centric features for people living with Parkinson's disease and essential tremor - New Informity™ ...
Shares of automotive companies climbed last Thursday as U.S. President Donald Trump eased the car tariff threat following a meeting with European Commission President Jean-Claude Juncker.
On July 24, Abbott Laboratories (ABT) ended the trading day at $64.40 per share. Currently, the stock is trading higher than its 50-day moving average of $62.45 and its 200-day moving average of $60.75.
During Abbott Laboratories’ (ABT) second-quarter earnings release on July 18, the company increased its fiscal 2018 guidance. This move was triggered by the company’s strong performance in the quarter. ABT stock rose ~3.1% on the day of its earnings announcement.
As discussed previously, analysts expect DaVita (DVA) to post revenue of $2.877 billion, adjusted net income of ~$175.97 million, and non-GAAP EPS of ~$0.97 in Q2 2018. Of the ten analysts tracking DaVita, five recommend “strong buy,” four recommend “hold,” and one recommends “sell.”
Abbott Laboratories’ (ABT) Diabetes segment registered second-quarter sales growth of ~40.0%, reaching $470.0 million. The Diabetes segment’s strong performance was driven by the continued uptake of Abbott’s Freestyle Libre CGM (continuous glucose monitoring) device. The device was approved by the FDA in September 2017. Abbott Laboratories gained market share in the second quarter in the diabetes market space from competitors such as Medtronic (MDT) and Dexcom (DXCM) due to the strong momentum in its Freestyle Libre adoption.
Q2 Results: What Drove Its Robust Growth? Abbott Laboratories (ABT) reported robust second-quarter revenues in its Medical Devices segment, as we discussed in the previous article. ABT’s heart failure and neuromodulation sales rose ~1.0%, and ~5.8%, respectively, in the second quarter on an organic basis.